iSpecimen Inc.

iSpecimen Inc. has completed the acquisition of two artificial intelligence products from Foldlab AI Ltd. for an aggregate purchase price of $4.5 million. The acquisition includes AI software, models, source code, data rights, and intellectual property related to disease-associated protein discovery and disease trend prediction. The purchase price consists of $750,000 in cash, up to $1.25 million in milestone payments, and $2.5 million in iSpecimen's common stock (2,907,977 shares). The stock consideration is subject to a five-year lock-up agreement. This acquisition marks iSpecimen's expansion into AI-powered disease intelligence, complementing its existing biospecimen marketplace.

iSpecimen Inc. entered into a Settlement Agreement and Mutual Release with WestPark Capital, Inc., resolving an arbitration where WestPark had sought nearly $270,000 in damages. Under the agreement, iSpecimen paid WestPark $97,500, and the arbitration was dismissed with prejudice. The settlement also terminates the Engagement Agreements for investment banking services, including those related to a public offering that raised approximately $4.0 million, and includes a mutual general release of claims.

iSpecimen Inc. announced the closing of its public offering, raising approximately $5.0 million. The offering included 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 shares. The company plans to use the proceeds for repayment of outstanding liabilities, potential acquisitions, marketing and advertising services, and working capital.

iSpecimen Inc. announced the pricing of its public offering, aiming to raise approximately $5 million through the sale of common stock and/or pre-funded warrants. The offering price is set at $1.30 per share or $1.2999 per pre-funded warrant. The company intends to utilize the proceeds for various purposes, including the repayment of outstanding liabilities, potential acquisitions, investments in new technologies, marketing, and general working capital. The offering, with E.F. Hutton & Co. as the exclusive placement agent, is anticipated to close on August 7, 2026.

iSpecimen Inc. filed an amendment for a proposed public offering of up to 2,092,050 shares of common stock and an equal number of pre-funded warrants, with an assumed public offering price of $2.39 per share. This follows a May 2026 private placement that raised approximately $2.5 million gross proceeds. The company also noted two recent reverse stock splits, 1-for-20 in September 2024 and 1-for-40 in April 2026.

iSpecimen Inc. announced the completion of Milestone 3 in its digital transformation program, powered by SalesStack Solutions. This milestone, completed on July 9, 2026, involved a payment of $700,000 to SalesStack Solutions Corp. The completion of Milestone 3 brings additional marketplace features, broader geographic rollout, and deeper integrations with partner ecosystems, building on previous achievements.

iSpecimen Inc. filed an Amendment No. 1 to its Form S-1 registration statement for a public offering of up to 1,515,152 shares of common stock and up to 1,515,152 pre-funded warrants. The assumed public offering price is $2.64 per share, with pre-funded warrants exercisable at $0.0001 per share. The amendment clarifies the use of proceeds, noting that "outstanding debt" refers to accounts payable and accrued obligations, and allocates approximately $700,000 for potential acquisitions.

iSpecimen Inc. filed an S-1 registration statement for a proposed offering of up to 1,544,402 shares of common stock and pre-funded warrants. The offering will be on a best-efforts basis with an assumed public offering price of $2.59 per share. This follows a May 2026 private placement that raised approximately $2.5 million and a 1-for-40 reverse stock split effective April 27, 2026.

iSpecimen Inc. received a notice from Nasdaq on May 29, 2026, indicating non-compliance with the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market. The company's reported stockholders' equity was $814,038 as of March 31, 2026, and it also fails to meet alternative listing standards. The notice does not immediately affect the trading of its common stock, and iSpecimen plans to submit a compliance plan within 45 days.

iSpecimen Inc. reported a significant decline in Q1 2026 revenue to $156,009, an 85.2% decrease from $1,057,510 in Q1 2025, while its net loss widened by 37.2% to $2.28 million. The company also disclosed a negative working capital of $2.12 million and an accumulated deficit of $84.63 million as of March 31, 2026, raising substantial doubt about its ability to continue as a going concern. Management is implementing cost-cutting measures, including workforce reductions, and plans to generate additional revenue, but cannot assure success.